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or any given receptor, there are mechanisms that regulate 
the activation of signal transduction pathways,  as well 
as mechanisms that extinguish those signaling pathways. Re- 
sponding to environmental signals requires  that both posi- 
tive and negative regulation proceed in an ordered manner. 
Much research has focused on lymphocyte antigen receptor- 
induced signal transduction pathways, and an understanding 
of some of the initial events has been gained. The mecha- 
nisms that terminate signaling are equally important but less 
well understood. The inability to properly extinguish activa- 
tion cascades may result in inappropriate responses and per- 
haps even cell death. Concerning lymphocyte antigen receptors, 
antigen recognition results in the activation of intracellular 
protein tyrosine kinases, particularly members of the Src family 
kinases, as well as the ZAP-70/syk kinases. The key to antigen- 
induced signal transduction is the phosphorylation of crit- 
ical tyrosines within the cytoplasmic domains of the TCR 
CD3/g" chain complex or the oe and 3  chains of the B cell 
antigen receptor (BCR) (1-3).  The critical tyrosines are lo- 
cated within a characteristic  sequence motif termed immu- 
noreceptor tyrosine-based  activation motif (ITAM).  Inac- 
tivating antigen receptors requires dephosphorylation, yet the 
involved enzyme(s) or process(es) have not previously been 
identified. Several recent reports, including one in this issue, 
provide important information about the mechanisms of BCR 
inactivation (3a-6). 
Potential  insight  into  the  negative  regulation  of im- 
munoreceptors was gained by the discovery that the motheaten 
mice (me) harbor a mutation in the SHP gene (also known 
as PTP1C, HCP, SH-PTP1) (7, 8). The mutation renders me 
mice deficient in SHP protein. SHP is an SH2 domain con- 
taining protein tyrosine phosphatase (PTPase) and belongs 
to a subfamily that contains another mammalian member, 
syp (also known as PTP2C, PTP1D and SH-PTP2), and a 
Drosophila member, corkscrew (csw) (9-18).  syp is thought to 
function in the positive regulation of receptor tyrosine ki- 
nases and to be the mammalian orthologue of csw. In con- 
trast, the phenotype of the me mice suggests that SHP func- 
tions in the negative regulation of leukocyte activation, me 
mice have  numerous immunological disorders,  including 
chronic macrophage and neutrophil activation, lymphopenia, 
and circulating autoantibodies (19). The B lymphocyte popu- 
lations are markedly disproportionate; there is an absence of 
CD5-  B lymphocytes (B2 cells), while the CD5 § B lym- 
phocytes (B1 cells) are present and increased in relative numbers 
in the spleen. The B1 lymphocytes are activated and produce 
autoantibodies. Indeed, in both the spleen and lymph nodes 
there are atypical plasmacytoid cells that accumulate immuno- 
globulin as insoluble inclusion bodies. The phenotype of me 
mice suggests that SHP regulates B lymphocyte differentia- 
tion and may regulate BCR signal transduction, albeit there 
may be fundamental differences between B1 and B2 lym- 
phocytes. 
In this issue, Pani et al. provide support for SHP-negative 
regulation of the  BCR  (6).  Using  a  CD5 + B  cell  line, 
CH12, Pani and co-workers convincingly demonstrate an as- 
sociation between SHP (PTP1C) and the BCR. Significantly, 
cross-linking of the BCR results in an immediate disassocia- 
tion of the phosphatase. These data imply that SHP may func- 
tion to keep the BCR inactivated  before stimulation. Fur- 
thermore, these investigators demonstrate that me B cells are 
increased in responsiveness to suboptimal concentrations of 
BCR cross-linking (6). Therefore, SHP may also regulate the 
threshold with which the BCR responds to antigen. 
Further support for this model comes from the recent work 
of Cyster and Goodnow (4). Using B cells from a transgenic 
mouse expressing anti-hen egg lysozyme crossed onto the 
me background, these investigators have demonstrated accen- 
tuated signaling induced by antigen. Thus, SHP functions 
in the negative regulation of the BCR. By using bone marrow 
chimeras to examine the antigen threshold required for clonal 
deletion, it was demonstrated that a soluble form of lyso- 
zyme autoantigen was able to arrest and delete immature B 
cells in the bone marrow, whereas B cells with normal SHP 
were only arrested and deleted if the same autoantigen was 
displayed on the surface  of neighboring cells in a highly 
multivalent form. Therefore, the absence of SHP results in 
a reduced signaling threshold and increased sensitivity to self- 
antigen. The function of SHP in B cell development is crit- 
ical in determining the threshold by which cells respond to 
self-antigens. 
Insight into the molecular mechanisms by which SlIP in- 
activates the B cell receptor has come from two further studies 
(3a, 5). It was previously demonstrated that BCR signal trans- 
duction can be abolished by cross-linking with Fc3,RIIB (20, 
21), indicating that Fc3~RIIB functions to block BCR sig- 
naling.  A  13-amino acid sequence within the cytoplasmic 
domain of Fc"/RIIB is responsible for the inhibitory signal. 
Furthermore, a specific tyrosine residue within the 13 amino 
acids is critical  to the process (21). This sequence motif is 
termed an immunoreceptor tyrosine-based  inhibitory motif 
(ITIM). D'Ambrosio and co-workers demonstrate that SHP 
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Figure  1.  Phosphotyrosyl peptide sequences that bind SHP SH2 do- 
mains and serve to increase catalytic activity  (3a, 6, 30). The numbers 
indicate the position  of the first amino acid in the sequence. 
binds to the ITIM within the cytoplasmic domain of FcyRIIB 
(5). Importantly, BCR cross-linking and tyrosine phosphory- 
lation of the ITIM sequence is required for the association 
with SHP. Evidence that this association is important in the 
negative regulation of BCR signaling comes from the obser- 
vation that FcTRIIB does not block signaling in B cells from 
me  mice (5,  6). 
Given the specificity of FcTR.IIB, it is unlikely that the 
SHP/FcTRIIB interaction is the only mechanism of nega- 
tive BCR regulation. It is satisfying, therefore, that a second 
potential mechanism has been reported by Doody and col- 
leagues (3a). These researchers report that BCR cross-linking 
results in the rapid association of SHP with the transmem- 
brane lectin, CD22. CD22 will associate with the BCR and 
becomes tyrosine phosphorylated in response to BCR liga- 
tion (22-24).  The association  of SHP with CD22 is medi- 
ated through three distinct phosphotyrosine residues within 
the cytoplasmic  domain of CD22 and the amino-terminal 
SH2 domain of SHP. Importantly, the three phosphotyro- 
sine residues that interact with SHP are located within regions 
that are similar to the ITIM sequence of FcyRIIB (Fig.  1). 
The identification of three distinct sites within the cytoplasmic 
domain of CD22 suggests that these sites may be redundant. 
Antibody-induced clustering of CD22 before BCR ligation 
increases the proliferative capacity, suggesting that CD22 may 
deliver a negative regulatory signal (3a). This observation is 
supported  by earlier work that demonstrated that monodonal 
antibody-induced cross-linking of CD22 can potentiate BCR 
signaling (25,  26). 
To terminate signaling, SHP must only dephosphorylate 
tyrosine residues at the appropriate time. Since SHP is a cyto- 
solic enzyme, preventing SHP from dephosphorylating sub- 
strates prematurely implies that the catalytic activity must 
be regulated. Indeed, this is the case. Full-length SHP has 
poor phosphatase activity.  However,  truncation of the SH2 
domains results in a marked increase in enzymatic activity 
(3a, 27, 28). This suggests that the catalytic activity of SHP 
may be regulated by an allosteric mechanism involving the 
SH2 domains. It is of much interest, therefore, that peptides 
that bind the SH2 domains of either syp or SHP result in 
a dramatic increase in phosphatase activity (3a,  5, 29, 30). 
Thus, SHP SH2 domains serve to both recruit the enzyme 
to appropriate sites of tyrosine phosphorylation and to regu- 
late the catalytic activity. Importantly, synthetic phosphopep- 
tides representing the potential sites of tyrosine phosphory- 
lation within  Fc~RIIB  and CD22  serve to  increase  SHP 
catalytic activity (3a, 5). Therefore, the ITIM sequences rep- 
resent SHP binding sites, and they function to increase phos- 
phatase activity. A comparison of peptides that stimulate SHP 
activity indicates  sequence  similarities  (Fig.  1). 
A potential model to account for the termination of BCR 
signal transduction is that tyrosine phosphorylation of ei- 
ther CD22 or FcTRIIB recruits SHP to the membrane and, 
upon association with the BCR, allows for dephosphoryla- 
tion of appropriate substrates (Fig. 2). It is unknown whether 
these interactions account for the association with the BCR 
in unstimulated cells, as observed by Pani et al.  (6). It will 
be  important,  therefore,  to  determine whether  SHP  can 
directly bind the BCR, and whether a direct association is 
another mechanism to inactivate  the receptor. 
The phenotype of me  mice suggests that SHP functions 
to regulate activation and differentiation of multiple hema- 
topoietic lineages including macrophages, neutrophils, lym- 
phocytes, and erythrocytes.  Thus, SHP does not exclusively 
regulate the BCR but other receptors as well Indeed, SHP 
has been demonstrated to associate with the IL-3 and erythro- 
poietin receptors and c-kit (31-33).  Taken together, the data 
suggests that SHP has a fundamental role in the negative regu- 
lation of many immunoreceptors  and that it accounts for the 
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Figure 2.  A potential model for the inactivation of 
BCR signaling. BCR ligation results in the tyrosine 
phosphorylation of CD22 and F~RIIB cytoplasmic  do- 
main. SHP binds via the SH2 domains to phosphotyro- 
sine sites in CD22 and FcTRIIB, resulting in the local- 
ization and activation of phosphatase activity. Upon 
binding  of SHP, association of either CD22 or Fc~RIIB 
with the BCR terminates signaling. severity  of the  disease  in  me  mice.  The  recruitment  and 
activation of SHP is necessary for the termination of signal 
transduction for many immunoreceptors, including antigen, 
cytokine, and growth factor receptors.  It is interesting that 
the transmembrane PTPase, CD45 is critical for the activa- 
tion of lymphocyte Src family members and is necessary for 
antigen-induced signaling. Apparently, for antigen receptors, 
there are PTPases at the beginning and end of the activation 
process! 
I thank my colleagues  for helpful discussions  and Drs. John Cambier, Jason Cyster, and Chris Goodnow 
for providing preprints and discussing unpublished observations. 
Address correspondence  to Dr. Matthew L. Thomas, Howard Hughes Medical Institute and Department 
of Pathology, Box 8118, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, 
MO 63110. 
Received for publication  I3 March  1995. 
References 
1.  Weiss, A., and D.R. Littman.  1994. Signal transduction by 
lymphocyte antigen receptors. Cell. 76:263-274. 
2.  Cambier, J.C., C.M. Pleiman, and M.R. Clark. 1994. Signal 
transduction by the B cell antigen receptor and its coreceptors. 
Annu.  Rev. Immunol.  12:457-486. 
3.  Gold,  M.R., and A.L. DeFranco. 1994. Biochemistry  orB lym- 
phocyte activation. Adv. Imm'anol. 55:221-295. 
3a. Doody, G.M., L.B.  Justement, C.C. Delibrias, R.J. Matthews, 
J. Lin, M.L. Thomas, and D.T. Fearon. 1995. Restriction of 
B lymphocyte activation by CD22 and the protein tyrosine 
phosphatase SHE Science (Wash. DC). In press. 
4.  Cyster,  J.G., and C.C. Goodnow. 1995. Protein tyrosine phos- 
phatase 1C negatively regulates antigen receptor signaling in 
B lymphocytes and determines thresholds for negative selec- 
tion. Immunity.  2:13-24. 
5.  D'Ambrosio, D., K.H. Hippen, S.A. Minskoff, I. Mellman, 
K.A. Siminovitch, G. Pani, and J.C. Cambier. 1995. IrI'PIC 
recruitment and activation by Fcq,  KIIBI: a molecular basis for 
negative signal cooperativity with the B cell antigen receptor. 
Science (Wash. DC).  In press. 
6.  Pani, G., M. Koz!owski,  J.C. Cambier, G.B. Mills, and K.A. 
Siminovitch. 1995. Identification of the tyrosine phosphatase 
PTPIC as a B cell antigen receptor-associated  protein involved 
in the regulation of B cell signalling.  J. Exp. Med. 181:XXX- 
XXX. 
7.  Shukz, L.D., P.A. Schweitzer, T.V. Rajan, T. Yi, J.N. Ihle, 
KJ. Matthews, M.L. Thomas, and D.K. Beier. 1993. Muta- 
tions at the murine motheaten locus are within the hemato- 
poietic cell protein-tyrosine phosphatase (Hcph)  gene. Cell. 
73:1445-1454. 
8.  Tsui, H.W., K.A. Siminovitch, L. de Souza, and F.W.L. Tsui. 
1993. Motheaten and viable motheaten mice have mutations 
in the haematopoietic cell phosphatase gene. Nature Genet, 4: 
124-129. 
9.  Feng,  G.-S., C.-C. Hui, and T. Pawson. 1993. SH2-containing 
phosphotyrosine phosphatase as a target of protein-tyrosine 
kinases. Science (Wash. DC).  259:1607-1611. 
10.  Vogel, W., K. Lammers,  J. Juang, and A. UUrich. 1993. Acti- 
vation of a phosphotyrosine  phosphatase  by tyrosine  phosphory- 
lation. Science (Wash. DC).  259:1611-1614. 
t955  Thomas 
11.  Zhao, Z.,  P. Bouchard, C.D. Diltz, S.-H. Shen, and E.H. 
Fischer. 1993. Purification and characterization of a protein 
tyrosine phosphatase containing SH2 domains.  J. Biol. Chem. 
268:2816-2820. 
12.  Adachi, M., M. Sekiya, T. Miyachi, K. Matsuno, Y. Hinoda, 
K. Imai, and A. Yachi. 1992. Molecular cloning of a novel 
protein-tyrosine  phosphatase  SH-PTP3 with sequence similarity 
to the src-homology region 2. FEBS (Fed. Eur. Biochem. Soc.) 
Lett. 314:335-339. 
13.  Freeman, Jr., R.M., J. Plutzky, and B.G. Neel. 1992. Iden- 
tification of a human  src homology 2-containing protein- 
tyrosine-phosphatase: a putative homolog of Drosophila cork- 
screw. Proc. Natl.  Acad. Sci. USA.  89:11239-11243. 
14.  Matthews, R.J., D.B. Bowne, E. Flores, and M.L. Thomas. 
1992. Characterization of hematopoietic intracellular protein 
tyrosine phosphatases: description of a phosphatase containing 
an SH2 domain  and another enriched  in proline-, glutamic acid-, 
serine-, and threonine-rich sequences. Mot. Celt. Biol. 12:2396- 
2405. 
15.  Perkins, L.A., I. Larsen, and N. Perrimon. 1992. corkscrew en- 
codes a putative protein tyrosine phosphatase that functions 
to transduce the terminal signal from the receptor tyrosine ki- 
nase torso. Cell. 70:225-236. 
16.  Plutzky, J., B.G. Neel, and R.D. Rosenberg. 1992. Isolation 
of a src homology 2-containing  tyrosine  phosphatase. Proa Natl. 
Acad. Sci. USA.  89:1123-1127. 
17.  Yi, T., J.L. Cleveland, and J.N. Ihle. 1992. Protein tyrosine 
phosphatase containing SH2 domains: characterization, pref- 
erential expression in hematopoietic cells, and localization to 
human chromosome 12p12-p13. Mol.  Cell. Biol. 12:836-846. 
18.  Shen, S.-H., L. Bastien, B.I. Posner, and P. Chr~tien. 1991. 
A protein-tyrosine  phosphatase with sequence similarity to the 
SH2 domain of the protein-tyrosine kinases. Nature (Lond.). 
352:736-739. 
19.  Shultz, L.D.  1991. Hematopoiesis and models of immuno- 
deficiency. Semin.  Immunol.  3:397-408. 
20.  Amigorena, S., C. Bonnerot, J.R. Drake, D. Choquet,  W. 
Hunziker, J.-G. Guillet, P. Webster, C. Sautes, I. MeUman, 
and W.H. Fridman. 1992. Cytoplasmic domain heterogeneity 
and functions of IgG Fc receptors in B lymphocytes. Science (Wash. DC).  256:1808-1812. 
21.  Muta, T., T. Kurosaki, Z. Misulovin, M. Sanchez, M.C. Nus- 
senzweig, and J.V. Ravetch. 1994. A 13-amino-acid motif in 
the cytoplasmic  domain of F~RllB modulates B-cell receptor 
signalling. Nature (Lond.). 368:70-73. 
22.  Leprince,  C., K.E. Draves, R.L. Geahlen,  J.A. Ledbetter, and 
E.A. Clark. 1993. CD22 asssociates with the human surface 
IgM-B-cell antigen receptor  complex. Proa Natl. Acad. Sci. USA. 
90:3236-3240. 
23.  Peaker,  C.J.G., and M.S. Neuberger. 1993. Association  of CD22 
with the B cell  antigen receptor. Eur,  J. Immunol. 23:1358-1363. 
24.  Munro, S., B.J.E.G. Bast, K.J. Colley, and T.F. Tedder. 1992. 
The B lymphocyte surface antigen CD75  is not an c~-2,6- 
sialytransferase  but is a carbohydrate antigen, the production 
of which requires the enzyme. Cell. 68:1003. 
25.  Pezzutto, A., B. D6rken, G. Moldenhaner, and E.A. Clark. 
1987. Amplification of human B cell activation by a mono- 
clonal antibody to the B cell-specific  antigen CD22, Bp 130/ 
140. J. Immunol.  138:98-103. 
26.  pezzutto, A., P.S. Rabinovitch, B. D6rken, G. Moldenhauer, 
and E.A. Clark. 1988. Role of the CD22 human B cell an- 
tigen in B cell triggering by anti-immunoglobulin.J. Immunol. 
140:1791-1795. 
27.  Pei, D., B.G. Neel, and C.T. Walsh. 1993. Overexpression, 
purification, and characterization of SHPTP1, Src homology 
2-containing  protein-tyrosine-phosphatase.  Pma Natl. Acad. Sci. 
USA.  90:1092-1096. 
28.  Townley,  P,., S.-H. Shen, D. Banville, and C. Ramachandran. 
1993. Inhibition of the activity of protein tyrosine phospha- 
tase 1C by its SH2 domains. Biochemistry. 32:13414-13418. 
29.  Pei,  D., U. Lorenz, U. Klingmiiller,  B.G. Ned, and C.T. Walsh. 
1994. Intramolecular regulation of protein tyrosine SH-FTPl: 
a new function for Src homology domains. Biochemistry. 33: 
15483-15493. 
30.  Sugimoto, S., T.J. Wandless, S.E. Shoelson, B.G. Ned, and 
C.T. Walsh. 1994. Activation of the SH2-containing protein 
tyrosine  phosphatase, SH-FI'P2, by phosphotyrosine-containing 
peptides derived  from insulin receptor substrate-l.J. Biol. Chem. 
269:13614-13622. 
31.  Yi, T., and J.N. Ihle. 1993. Association of hematopoietic cell 
phosphatase with c-Kit after stimulation with c-Kit ligand. 
Mol.  Cell. Biol. 13:3350-3358. 
32.  Yi, T., A.L.-F. Mui, G. Krystal, andJ.N. Ihle. 1993. Hemato- 
poietic cell phosphatase associates with the interleukin-3 (Ib3) 
receptor B chain and down-regulates  I1,-3 induced  tyrosine  phos- 
phorylation and mitogenesis. Mol.  Cell. Biol. 13:7577-7586. 
33.  Yi, T., J. Zhang, O. Miura, and J. Ihle. 1995. Hematopoietic 
cell phosphatase associates  with erythropoietin (Epo) receptor 
after epo-induced receptor tyrosine phosphorylation: iden- 
tification of potential binding sites. Blood. 85:87-95. 
1956  Commentary 